Key facts
- Biosion’s last known valuation is $182.3M (Dec 2020).
- It has raised $132.7M; the latest was Secondary Transaction - Private in Aug 2025.
- Notable investors include Addor Capital, Suzhou Guofa Venture Capital, Lapam Capital, GF Xinde Investment Management, Xiamen C&D Corporation — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Biosion
- ·The full record, as it builds
Funding rounds
No funding rounds for Biosion are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biosion
Developer of biomedical drugs intended for the treatment of immune and oncologic diseases. The company's antibody-based therapies discovery platforms accelerate the discovery and development of biomedical drugs through mono and bi-specific protein therapeutics, enabling greater treatment potential for patients with related diseases.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2017
- Employees
- 90
- Website
- biosion.com/
- Ownership
- Privately Held (backing)
Biosion doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biosion shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biosion in its N-PORT filings yet. We sweep new filings monthly.